The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
=== 20th century === During the 1970s and 80s, when the first thorough fundamental studies with nanoparticles were underway in the United States by Granqvist and Buhrman and Japan within an ERATO Project, researchers used the term ultrafine particles. However, during the 1990s, when the National Nanotechnology Initiative was launched in the United States, the term nanoparticle became more common, for example, see the same senior author's paper 20 years later addressing the same issue, lognormal distribution of sizes.
Although a majority of OECD countries protect the right of employees to vote for directors on boards of corporations (usually at least one-third), Australia has not yet passed a general law by amending the Corporations Act 2001, the Fair Work Act 2009 or state laws for worker directors. However, Australia does have board-level employee representation (or "codetermination") in occupational pensions, and several specific sectors. First, under the Hawke-Keating government Australia enacted a leading model for voice in worker's capital, now in the Superannuation Industry (Supervision) Act 1993 section 89, requiring an "equal numbers of employer representatives and member representatives" on the board of directors or trustees in a super-fund. In 2010 a proposal was made to amend this for so called "independent directors" to be required to take the balance of power, appointed by the incumbent board, even though the evidence suggested this would be a step backwards. No changes were passed. There is not yet express legislation to require that asset managers, to whom investment and shareholder voting was outsourced, must follow the voting policies set by elected representatives on superannuation fund boards, as is found in Switzerland.
Thus, Medea as a wife kills Creon and Glauce in the act of vengeance, and Medea as a mother thinks her children will be better off killed by her hand than left to suffer at the hands of an enemy intent on vengeance. Medea is often described as having a "heroic temper" and a strong motivation to avoid the laughter of her enemies, "even at the cost of decisions that contradict self-interest, personal safety, or strongly held moral beliefs". Although some may say that her motive was jealousy over Jason’s new bride, her pride also made her unwilling to let her enemies, in this case Jason and his new wife, look down on her. Medea stated that "her enemies [would] cause her pain and rejoice," and that her priority was to "avoid her enemies’ derision." Although the murder of her children would cause her pain, Medea’s temperament caused her to prioritize Jason’s unhappiness over anything else.
Blue Shift was announced in the second quarter of 2000 as part of an upcoming Dreamcast port of Half-Life. While the port was developed by Captivation Digital Laboratories, Blue Shift was developed by Gearbox Software, who also developed the first Half-Life expansion, Opposing Force. The game had the working title Half-Life: Guard Duty; publisher Sierra Entertainment announced the name Blue Shift on August 30, 2000. As with Opposing Force, the title has a double meaning, referring to both the blue shift light phenomenon and the name of Barney's shift. The Dreamcast port would include higher detail models and textures that were double the polygon count of Valve's original Half-Life models. At the European Computer Trade Show in September 2000, information about Blue Shift's story and development direction was revealed, along with a release date of November 1, 2000, for the Dreamcast version of Half-Life. The port was delayed by Sierra to ensure the "high expectations of consumers" were met, anticipating release by the end of the year. On March 29, 2001, Sierra announced that Blue Shift would also be released for Windows as a standalone game that would not require the original Half-Life to run. The new models developed for the Dreamcast version would also be included in the PC version as the Half-Life High Definition pack, and could be applied to Half-Life and Opposing Force. At the E3 2001, Gearbox announced that Blue Shift was complete and exhibited a playable version. It was released on June 12, 2001, in North America, and on June 15 in Europe.
The HIC of leaf waxes can be summarized as the δD of rain water, with three main fractionation steps: evaporation from soil water, transpiration from leaf water, and lipid biosynthesis, which can be combined and measured as the net fractionation, εl/w. With ever-improving measurement techniques for single molecules, and correlation with other independent proxies in the geological record that can help constrain some variables, investigating the HIC of leaf waxes can be extremely productive. Leaf wax δD data has been successfully applied to improving our understanding of climate driven changes in terrestrial hydrology, by showing that ocean circulation and surface temperature have a significant effect on continental precipitation. Leaf wax δD values have also been used as records of paleoaltimetry to reconstruct the elevation gradients in ancient mountain ranges based on the effect of altitude on rain water δD.
Sources: en.wikipedia.org
== Secretion == A typical adult human stomach will secrete about 1.5 liters of gastric juice daily. Gastric juice is the combination of gastric gland secretions including the main component of hydrochloric acid (gastric acid), gastric lipase and pepsinogen. Once in the stomach pepsinogen is changed by gastric acid to the digestive enzyme pepsin adding this enzyme to the gastric juice. In humans, the pH of gastric acid is between one and three, much lower than most other animals, but is very similar to that of carrion eating carnivores, needing extra protection from ingesting pathogens. Gastric acid secretion is produced in several steps. Chloride and hydrogen ions are secreted separately from the cytoplasm of parietal cells and mixed in the canaliculi. This creates a negative potential of between −40 and −70 mV across the parietal cell membrane that causes potassium ions and a small number of sodium ions to diffuse from the cytoplasm into the parietal cell canaliculi. Gastric acid is then secreted along with other gland secretions into the gastric pit for release into the stomach lumen. The enzyme carbonic anhydrase catalyses the reaction between carbon dioxide and water to form carbonic acid. This acid immediately dissociates into hydrogen and bicarbonate ions. The hydrogen ions leave the cell through H+/K+ ATPase antiporter pumps. At the same time, sodium ions are actively reabsorbed. This means that the majority of secreted K+ (potassium) and Na+ (sodium) ions return to the cytoplasm.
== Diaphragm and peristaltic pumps == In order to avoid leakage at the packing or seal particularly when a liquid is dangerous, toxic, or noxious, diaphragm pumps are used for metering. Diaphragm pumps have a diaphragm through which repeated compression/decompression motion is transmitted. The liquid does not penetrate through the diaphragm, so the liquid inside the pump is sealed off from the outside. Such motion changes the volume of a chamber in the pump head so that liquid enters through an inlet check valve during decompression and exits through an outlet check valve during compression, in a manner similar to piston pumps. Diaphragm pumps can also be made which discharge at fairly high pressure. Diaphragm metering pumps are commonly hydraulically driven. Peristaltic pumps use motor-driven rollers to roll along flexible tubing, compressing it to push forward a liquid inside. Although peristaltic pumps can be used to meter at lower pressures, the flexible tubing is limited in the level of pressure it can withstand.
MR + CO2 → RCO2M where M = Li or MgBr and R = alkyl or aryl. In metal carbon dioxide complexes, CO2 serves as a ligand, which can facilitate the conversion of CO2 to other chemicals. The reduction of CO2 to CO is ordinarily a difficult and slow reaction:
== Purpose == Carbohydrate is one of three major macronutrients found in food. The other major macronutrients are protein and fat. Carbohydrate in its simplest form is known as glucose and can contribute to a rise in blood sugar. In people with diabetes, the body's ability to keep blood sugar at a normal level is impaired. Dietary management of carbohydrate consumed is one tool used to help optimize blood sugar levels. Carbohydrate is found in a number of foods including fruits, starchy vegetables (such as peas, potatoes, and corn), grains, milk and yogurt, legumes, and desserts. In general, foods such as meat, eggs, cheese, fats, and non-starchy vegetables (such as greens and broccoli) have little to no carbohydrate. Other foods free of carbohydrate include small quantities of certain condiments, unsweetened coffee and tea, and sugar free sodas. Carbohydrate content of foods is listed on the Nutrition Facts panel as "total carbohydrate". Some food labels will list specific types of carbohydrate, such as "fiber, sugar, or other carbohydrate". With carbohydrate counting, the "total carbohydrate" is used as the carbohydrate amount. Carbohydrate counting can be done by either adding up grams of total carbohydrate or adding "carbohydrate units". A carbohydrate unit is simply 15 g of carbohydrate.
Listeria monocytogenes, some species of Rickettsia, Shigella flexneri and other intracellular germs escape from phagocytic vacuoles by coating themselves with a capsule of actin filaments. L. monocytogenes and S. flexneri both generate a tail in the form of a "comet tail" that gives them mobility. Each species exhibits small differences in the molecular polymerization mechanism of their "comet tails". Different displacement velocities have been observed, for example, with Listeria and Shigella found to be the fastest. Many experiments have demonstrated this mechanism in vitro. This indicates that the bacteria are not using a myosin-like protein motor, and it appears that their propulsion is acquired from the pressure exerted by the polymerization that takes place near to the microorganism's cell wall. The bacteria have previously been surrounded by ABPs from the host, and as a minimum the covering contains Arp2/3 complex, Ena/VASP proteins, cofilin, a buffering protein and nucleation promoters, such as vinculin complex. Through these movements they form protrusions that reach the neighbouring cells, infecting them as well so that the immune system can only fight the infection through cell immunity. The movement could be caused by the modification of the curve and debranching of the filaments. Other species, such as Mycobacterium marinum and Burkholderia pseudomallei, are also capable of localized polymerization of cellular actin to aid their movement through a mechanism that is centered on the Arp2/3 complex.
Sources: en.wikipedia.org
==== Metabolism ==== Minoxidil is a prodrug of minoxidil sulfate, which can be formed both systemically and locally within hair follicles. This active metabolite is 14-fold more potent than minoxidil in stimulating cysteine incorporation in cultured rodent hair follicles ex vivo. Similarly to minoxidil, it also stimulates hair follicle growth. Minoxidil is sulfated into minoxidil sulfate by at least four cytosolic sulfotransferase enzymes found in skin, scalp, smooth muscle, liver, and fibroblasts. The primary sulfotransferase involved in sulfation of minoxidil in hair follicles is SULT1A1, whereas in the liver, it is SULT2A1. Expression of this enzyme has been found to predict the effectiveness of topical minoxidil. Oral minoxidil is subject to first-pass metabolism, including rapid and extensive metabolism in the liver. A majority of orally administered minoxidil, about 90%, is metabolized in the liver via glucuronidation, hydroxylation, and sulfation, with glucuronidation being the primary metabolic pathway and minoxidil glucuronide being the predominant metabolite of minoxidil. Conversely, topical minoxidil bypasses the first pass through the liver and is not subject to first-pass metabolism. Similarly, sublingual minoxidil also bypasses first-pass metabolism.
August 19–September 1: The Viet Minh seizes control of Hanoi and much of the former Empire of Vietnam after the surrender of Japan, proclaiming the Democratic Republic of Vietnam and initiating civil conflicts. September 2: Surrender of Japan - The Empire of Japan surrenders unconditionally to the United States, officially ending World War II. General Douglas MacArthur presides over the occupation of Japan, and freezes out Russian and other allied representatives(V-J day). September 5: Igor Gouzenko, a Soviet agent working in the Soviet embassy in Canada, defects and provides proof to the Royal Canadian Mounted Police of a Soviet spy ring operating in Canada and the U.S. The revelations help change perceptions of the Soviet Union from an ally to a foe. October 25: Taiwan is transferred to the Republic of China from Japan. Initially the Chinese public was supportive of the transfer but later becomes less so as the newly appointed governor, General Chen Yi gains a reputation for being corrupt and mismanaging the island. Economic problems also occur as the governor extends the scope of the government monopoly over Taiwan's resources in order to sell these goods to the mainland to help fight the Communist forces. The conditions on the island later contribute to the February 28 incident. November: Iran crisis of 1946 - Stalin refuses to relinquish Soviet-occupied territory in Iran, beginning the Iran Crisis. Two short-lived pro-Soviet states, the Azerbaijan People's Government and the Republic of Mahabad, are formed. November 20: The Nuremberg trials begin.
The classic symptom of keratoconus is the perception of multiple "ghost" images, known as monocular polyopia. This effect is most clearly seen with a high contrast field, such as a point of light on a dark background. Instead of seeing just one point, a person with keratoconus sees many images of the point, spread out in a chaotic pattern. This pattern does not typically change from day to day, but over time, it often takes on new forms. People also commonly notice streaking and flaring distortion around light sources. Some even notice the images moving relative to one another in time with their heartbeat. The predominant optical aberration of the eye in keratoconus is coma. The visual distortion experienced by the person comes from two sources, one being the irregular deformation of the surface of the cornea, and the other being scarring that occurs on its exposed highpoints. These factors act to form regions on the cornea that map an image to different locations on the retina. The effect can worsen in low light conditions, as the dark-adapted pupil dilates to expose more of the irregular surface of the cornea. Significant retinal layer thickness reduction is observed in keratoconus, especially in younger patients (<30 years).
Furthermore, it can be triggered by severe acute illness, dehydration, extensive exercise, surgery, low-carbohydrate diets, or excessive alcohol intake. Proposed mechanisms for SGLT2-I induced "euglycemic DKA" include increased ketosis due to volume depletion combined with relative insulin deficiency and glucagon excess. SGLT2 inhibitors should be stopped before surgery and only recommenced when it is safe to do so. SGLT2 inhibitors may be used in people with type 1 diabetes, but the possibility of ketoacidosis requires specific risk management. Specifically, they should not be used if someone is also using a low carbohydrate or ketogenic diet.
This results from a generally inhibitory effect of norepinephrine on the enteric nervous system, causing decreases in gastrointestinal mobility, blood flow, and secretion of digestive substances. Noradrenaline and ATP are sympathetic co-transmitters. It is found that the endocannabinoid anandamide and the cannabinoid WIN 55,212-2 can modify the overall response to sympathetic nerve stimulation, which indicates that prejunctional CB1 receptors mediate the sympatho-inhibitory action. Thus cannabinoids can inhibit both the noradrenergic and purinergic components of sympathetic neurotransmission.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.